News brief­ing: Chi-Med en­trusts In­ma­gene with four pre­clin­i­cal pro­grams; Xofluza nets EU ap­proval for flu pre­ven­tion

Long­time Or­biMed part­ner Jonathan Wang is start­ing the year off at his lat­est ven­ture, In­ma­gene, with a slate of new pre­clin­i­cal drug can­di­dates.

The four pro­grams come from Chi-Med, which the CEO prais­es as “one of Chi­na’s flag­ship bio­phar­ma­ceu­ti­cal com­pa­nies.”

Chi-Med is grant­i­ng In­ma­gene ex­clu­sive op­tions to de­vel­op these drugs for im­munol­o­gy dis­eases but re­tain­ing the first right to com­mer­cial­iza­tion in main­land Chi­na. For each of the can­di­dates that its biotech part­ner ex­er­cis­es an op­tion on, Chi-Med can re­ceive up to $95 mil­lion in de­vel­op­ment mile­stones and $135 mil­lion in com­mer­cial mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER